Oxidative stress in cystic fibrosis lung disease: An early event, but worth targeting?

European Respiratory Journal

Volumn 44, Issue 1, 2014, Pages 17-19

  Hector, Andreas ^a   Griese, Matthias ^b   Hartl, Dominik ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTATHIONE; HYPOCHLOROUS ACID; MYELOPEROXIDASE; OXIDIZING AGENT; PROTEINASE; OXYGEN;

CYSTIC FIBROSIS; EDITORIAL; GLUTATHIONE METABOLISM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LUNG DISEASE; LUNG FUNCTION; NEUTROPHIL; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TARGETING; CHEMISTRY; METABOLISM;

CYSTIC FIBROSIS; GLUTATHIONE; HUMANS; OXYGEN;

EID: 84903842129     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00038114     Document Type: Editorial

References (31)

1. Galli F, Battistoni A, Gambari R, et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta 2012; 1822: 690-713.
2. Cantin AM, White TB, Cross CE, et al. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med 2007; 42: 15-31.
3. Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest 2013; 144: 266-273.
4. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-242.
5. Hartl D, Gaggar A, Bruscia E, et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012; 11: 363-382.
6. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16: 534-554.
7. Roum JH, Buhl R, McElvaney NG, et al. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993; 75: 2419-2424.
8. Rieber N, Hector A, Kuijpers T, et al. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012; 2012: 252460.
9. Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 2001; 30: 1440-1461.
10. Gao L, Kim KJ, Yankaskas JR, et al. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol 1999; 277: L113-L118.
11. Day BJ, van Heeckeren AM, Min E, et al. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary Pseudomonas infection. Infect Immun 2004; 72: 2045-2051.
12. Carr AC, Winterbourn CC. Oxidation of neutrophil glutathione and protein thiols by myeloperoxidase-derived hypochlorous acid. Biochem J 1997; 327: 275-281.
13. Kettle AJ, Turner, R, Gangell CL, et al. Oxidation contributes to low glutathione in the airways of children with cystic fibrosis. Eur Respir J 2014; 44: 122-129.
14. Fitzpatrick AM, Brown LA, Holguin F, et al. Levels of nitric oxide oxidation products are increased in the epithelial lining fluid of children with persistent asthma. J Allergy Clin Immunol 2009; 124: 990-996.
15. Hull J, Vervaart P, Grimwood K, et al. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997; 52: 557-560.
16. Cantin AM. Potential for antioxidant therapy of cystic fibrosis. Curr Opin Pulm Med 2004; 10: 531-536.
17. Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Nat Acad Sci USA 2006; 103: 4628-4633.
18. Griese M, Ramakers J, Krasselt A, et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 822-828.
19. Griese M, Kappler M, Eismann C, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med 2013; 188: 83-89.
20. Nash EF, Stephenson A, Ratjen F, et al. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Databases Syst Rev 2009; 1: CD007168.
21. Roum JH, Borok Z, McElvaney NG, et al. Glutathione aerosol suppresses lung epithelial surface inflammatory cellderived oxidants in cystic fibrosis. J Appl Physiol 1999; 87: 438-443.
22. Hartl D, Starosta V, Maier K, et al. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 2005; 39: 463-472.
23. Griese M, Latzin P, Kappler M, et al. a1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29: 240-250.
24. Griese M, Kappler M, Gaggar A, et al. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008; 32: 783-795.
25. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol a1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
26. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970.
27. Davis SD, Ferkol T. Identifying the origins of cystic fibrosis lung disease. N Engl J Med 2013; 368: 2026-2028.
28. Stocks J, Thia LP, Sonnappa S. Evaluation and use of childhood lung function tests in cystic fibrosis. Curr Opin Pulm Med 2012; 18: 602-608.
29. Singer F, Stern G, Thamrin C, et al. A new double-tracer gas single-breath washout to assess early cystic fibrosis lung disease. Eur Respir J 2013; 41: 339-345.
30. Aurora P, Stanojevic S, Wade A, et al. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2011; 183: 752-758.
31. Nauseef WM. Myeloperoxidase deficiency. Hematol Oncol Clin North Am 1988; 2: 135-158.